Prognostic role of long non-coding RNA USP30-AS1 in ovarian cancer: insights into immune cell infiltration in the tumor microenvironment

Abstract

Ovarian cancer represents a formidable gynecologic malignancy bearing a dismal prognosis owing to the dearth of reliable early detection approaches and a high recurrence rate. Long non-coding RNAs (lncRNAs) have garnered immense attention as key orchestrators involved in diverse biological processes and take part in cancer initiation and progression. The present study investigated the potential significance of lncRNA USP30-AS1 in ovarian cancer prognosis, as well as its putative association with immune cell infiltration in tumor immune microenvironment (TIME). By analyzing publicly available datasets, we identified six lncRNAs with prognostic prediction ability, including USP30-AS1. The results revealed a significant positive correlation of USP30-AS1 expression with the infiltration of immune cells such as Th1 cells, TFH, CD8 T cells, B cells, antigenpresenting dendritic cells (aDC), and plasmacytoid dendritic cells (pDC) in ovarian cancer specimens. These findings provide compelling evidence of the potential involvement of lncRNA in the regulation of the TME in ovarian carcinoma. The outcomes from this study underscore the potential of USP30-AS1 as a promising prognostic biomarker for ovarian cancer. Additionally, the findings offer significant insights into the plausible role of lncRNAs in modulating immune activities, thus adding to our understanding of the disease biology. Additional investigations are necessary to unravel the molecular mechanisms underpinning these connections and validate the results seen in independent cohorts and experimental models.

Tumor suppressor function of RBMS3 overexpression in EOC associated with immune cell infiltration

“…Ovarian cancer has the poorest prognosis and highest death rate among all gynecological malignancies, despite ranking tenth in the world for both morbidity and mortality among cancers that affect women [ 2 ]. Considering there are no distinct symptoms in the initial phases of the illness and there are no reliable screening methods, the majority of patients receive their diagnosis when the tumor has already widely metastasized [ 3 , 4 ]. The majority of patients have recurrence after a few years of treatment and ultimately succumb to chemotherapy-resistant illness, despite the success of cytoreductive surgery and chemotherapy (carboplatin and paclitaxel) [ 5 , 6 ].…”